A Performance Test Protocol for Closed System Transfer Devices Used During Pharmacy Compounding and Administration of Hazardous Drugs; Extension of Comment Period, 34674 [2017-15727]
Download as PDF
<![CDATA[
34674
Federal Register / Vol. 82, No. 142 / Wednesday, July 26, 2017 / Notices
Docket Office, 1090 Tusculum Avenue,
MS C–34, Cincinnati, Ohio 45226–1998.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
John Howard,
Director, National Institute for Occupational
Safety and Health, Centers for Disease Control
and Prevention.
Centers for Disease Control and
Prevention
[CDC–2016–0090; Docket Number NIOSH
288–A]
[FR Doc. 2017–15727 Filed 7–25–17; 8:45 am]
A Performance Test Protocol for
Closed System Transfer Devices Used
During Pharmacy Compounding and
Administration of Hazardous Drugs;
Extension of Comment Period
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institute for
Occupational Safety and Health
(NIOSH) of the Centers for Disease
Control and Prevention (CDC),
Department of Health and Human
Services (HHS).
Sunshine Act Meeting: Board of
Scientific Counselors, National Center
for Environmental Health/Agency for
Toxic Substances and Disease
Registry (BSC, NCEH/ATSDR)
AGENCY:
Notice and extension of
comment period.
ACTION:
On September 15, 2016 the
National Institute for Occupational
Safety and Health (NIOSH) of the
Centers for Disease Control and
Prevention (CDC), published a notice in
the Federal Register [81 FR 63482]
announcing a public meeting and
request for public comment on a draft
testing protocol.
Written comments were to be received
by December 7, 2016. NIOSH initially
extended the public comment period to
June 7, 2017 [81 FR 88687]. NIOSH
extended the comment period again to
August 30, 2017 [82 FR 25290]. NIOSH
is extending the public comment period
to close on February 28, 2018. The
longer timeframe will allow companies
to test the protocol with the proposed
challenge agents and permit full
participation in the protocol design
process.
SUMMARY:
FOR FURTHER INFORMATION CONTACT:
Deborah V. Hirst, NIOSH, Alice
Hamilton Laboratories, 1090 Tusculum
Avenue, MS R–5, Cincinnati, Ohio
45226, telephone (513) 841–4141 (not a
toll free number), Email: DHirst@
cdc.gov.
You may submit comments,
identified by CDC–2016–0090 and
Docket Number NIOSH 288–A, by either
of the following two methods:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: National Institute for
Occupational Safety and Health, NIOSH
mstockstill on DSK30JT082PROD with NOTICES
ADDRESSES:
VerDate Sep<11>2014
17:49 Jul 25, 2017
Jkt 241001
BILLING CODE 4163–19–P
Centers for Disease Control and
Prevention
TIMES AND DATES:
8:30 a.m.–4:30 p.m., EDT, September 13,
2017
8:30 a.m.–11:30 a.m., EDT, September
14, 2017
PLACE: CDC, 4770 Buford Highway,
Building 102, Conference Room 2202,
Atlanta, Georgia 30341.
STATUS: In accordance with section
10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92–463), the
Centers for Disease Control and
Prevention announces the meeting of
the BSC, NCEH/ATSDR. This meeting is
open to the public. The meeting room
accommodates approximately 60
people. The public is also welcome to
listen to the meeting by joining the
teleconference at the USA toll-free, dialin number, 1–888–790–2009 Passcode:
7865774. The deadline for notification
of attendance is August 30, 2017. The
public comment period is scheduled on
Wednesday, September 13, 2017 from
2:00 p.m. until 2:15 p.m.; from 2:40 p.m.
until 2:55 p.m.; and from 3:25 p.m. until
3:40 p.m., and on Thursday, September
14, 2017 from 10:10 a.m. until 10:25
a.m. EDT (15 minutes). Individuals
wishing to make a comment during
Public Comment period, please email
your name, organization, and phone
number by Monday, September 4, 2017
to Dr. William Cibulas at wic1@cdc.gov.
MATTERS TO BE CONSIDERED: The
Secretary, Department of Health and
Human Services (HHS) and by
delegation, the Director, CDC and
Administrator, NCEH/ATSDR, are
authorized under Section 301 (42 U.S.C.
241) and Section 311 (42 U.S.C. 243) of
the Public Health Service Act, as
amended, to: (1) Conduct, encourage,
cooperate with, and assist other
appropriate public authorities, scientific
institutions, and scientists in the
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
conduct of research, investigations,
experiments, demonstrations, and
studies relating to the causes, diagnosis,
treatment, control, and prevention of
physical and mental diseases and other
impairments; (2) assist states and their
political subdivisions in the prevention
of infectious diseases and other
preventable conditions and in the
promotion of health and wellbeing; and
(3) train state and local personnel in
health work. The BSC, NCEH/ATSDR
provides advice and guidance to the
Secretary, HHS; the Director, CDC and
Administrator, ATSDR; and the
Director, NCEH/ATSDR, regarding
program goals, objectives, strategies, and
priorities in fulfillment of the agency’s
mission to protect and promote people’s
health. The Board provides advice and
guidance that will assist NCEH/ATSDR
in ensuring scientific quality,
timeliness, utility, and dissemination of
results. The Board also provides
guidance to help NCEH/ATSDR work
more efficiently and effectively with its
various constituents and to fulfill its
mission in protecting America’s health.
The agenda items for the BSC Meeting
will include NCEH/ATSDR Director
Updates; Noise-Induced Hearing Loss;
NCEH/ATSDR Program Responses to
BSC Guidance and Action Items; Lead
Poisoning Prevention Program Updates;
Flint Registry; Revision of blood lead
level reference value (status); Discussion
of Legislative Requirements of new Lead
Exposure Poisoning Federal Advisory
Committee; Amyotrophic Lateral
Sclerosis (ALS) Program Update;
Environmental Health Tracking Program
update; updates from the National
Institute of Environmental Health
Sciences, the National Institute for
Occupational Safety and Health, the US
Department of Energy and the US
Environmental Protection Agency.
Agenda items are subject to change as
priorities dictate.
CONTACT PERSON FOR MORE INFORMATION:
Shirley Little, NCEH/ATSDR, CDC, 4770
Buford Highway, Mail Stop F–45,
Atlanta, Georgia 30341; Telephone 770/
488–0577, Email: snl7@cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
E:\FR\FM\26JYN1.SGM
26JYN1
]]>Agencies
[Federal Register Volume 82, Number 142 (Wednesday, July 26, 2017)]
[Notices]
[Page 34674]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-15727]
[[Page 34674]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[CDC-2016-0090; Docket Number NIOSH 288-A]
A Performance Test Protocol for Closed System Transfer Devices
Used During Pharmacy Compounding and Administration of Hazardous Drugs;
Extension of Comment Period
AGENCY: National Institute for Occupational Safety and Health (NIOSH)
of the Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice and extension of comment period.
-----------------------------------------------------------------------
SUMMARY: On September 15, 2016 the National Institute for Occupational
Safety and Health (NIOSH) of the Centers for Disease Control and
Prevention (CDC), published a notice in the Federal Register [81 FR
63482] announcing a public meeting and request for public comment on a
draft testing protocol.
Written comments were to be received by December 7, 2016. NIOSH
initially extended the public comment period to June 7, 2017 [81 FR
88687]. NIOSH extended the comment period again to August 30, 2017 [82
FR 25290]. NIOSH is extending the public comment period to close on
February 28, 2018. The longer timeframe will allow companies to test
the protocol with the proposed challenge agents and permit full
participation in the protocol design process.
FOR FURTHER INFORMATION CONTACT: Deborah V. Hirst, NIOSH, Alice
Hamilton Laboratories, 1090 Tusculum Avenue, MS R-5, Cincinnati, Ohio
45226, telephone (513) 841-4141 (not a toll free number), Email:
DHirst@cdc.gov.
ADDRESSES: You may submit comments, identified by CDC-2016-0090 and
Docket Number NIOSH 288-A, by either of the following two methods:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments.
Mail: National Institute for Occupational Safety and
Health, NIOSH Docket Office, 1090 Tusculum Avenue, MS C-34, Cincinnati,
Ohio 45226-1998.
John Howard,
Director, National Institute for Occupational Safety and Health,
Centers for Disease Control and Prevention.
[FR Doc. 2017-15727 Filed 7-25-17; 8:45 am]
BILLING CODE 4163-19-P
